Clinical Trial: LMBA02 Protocol for Patients With a Burkitt Lymphoma

Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional

Official Title:

Brief Summary: To explore in a multicenter international prospective randomized study (phase III) whether rituximab combined with the standard French LMB chemotherapy scheme results in a higher rate of EFS than the LMB chemotherapy scheme alone in patients older than 18 years with Burkitt lymphoma or ALL 3.

Detailed Summary:
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Current Primary Outcome: Event free survival from date of first randomization

Original Primary Outcome: Same as current

Current Secondary Outcome: Complete and partial response rate, overall survival, toxicity

Original Secondary Outcome:

  • - complete and partial response rate
  • - overall survival
  • - toxicity


Information By: Gustave Roussy, Cancer Campus, Grand Paris

Dates:
Date Received: September 12, 2005
Date Started: October 2004
Date Completion:
Last Updated: September 7, 2006
Last Verified: September 2006